COLUMBUS, Ohio Gene mutations that make cells cancerous can sometimes also make them more sensitive to chemotherapy. A new study led by cancer researchers at Ohio State University shows that a mutation present in some cases of acute leukemia makes the disease more susceptible to high doses of a particular anticancer drug.
The findings, from a Cancer and Leukemia Group B clinical cooperative group study led by Dr. Clara D. Bloomfield, an internationally known AML specialist at the Ohio State University Comprehensive Cancer Center, could change how doctors manage these patients.
The research is published online in the June 16 issue of the Journal of Clinical Oncology with an accompanying editorial.
The retrospective study shows that people with acute myeloid leukemia (AML) whose leukemic cells have mutations in the RAS gene are more likely to be cured when treated after remission with high doses of the drug cytarabine.
It also suggests that testing for RAS mutations might help doctors identify which AML patients should receive high-dose cytarabine as their post-remission therapy.
"This appears to be the first example in AML of a mutation in an oncogene that favorably modifies a patient's response to the dose of a routinely used chemotherapeutic drug," Bloomfield says.
"If confirmed, AML patients in the future will likely be screened for RAS mutations, and those who have one may get high-dose cytarabine for post-remission therapy rather than a stem-cell transplant."
Typically, people with newly diagnosed AML are treated first with drugs intended to drive the disease into complete remission, Bloomfield says. When that is achieved, patients are given additional chemotherapy, such as high-dose cytarabine, or more aggressive therapy, such as a stem cell transplant, to prevent relapse and to cure the malignancy.
But high-dose cytarabine is the better therapy for some patients, and the findi
'/>"/>
| Contact: Darrell E. Ward darrell.ward@osumc.edu 614-293-3737 Ohio State University Medical Center Source:Eurekalert |